This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Sulphonylureas and cardiovascular (CV) risk

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • since publication of the results of the University Group Diabetes Project (UGDP), the relationship between the use of sulphonylureas and increased cardiovascular risk has been questioned
    • patients treated with tolbutamide in the UGDP had a significantly higher cardiovascular rate of death than those given placebo (1)
  • a retrospective, inception cohort study investigating the use of oral hypoglycaemic agents and risk of cardiovascular disease has been undertaken (2)
    • study involved 5795 subjects - identified by their first-ever dispensation for an oral antidiabetic agent and grouped according to their use of such agents during follow-up
    • the study findings revealed that higher exposure to sulphonylureas was associated with increased mortality among patients newly treated for type 2 diabetes. The same relation was not observed with metformin

Reference:

  1. Meinert CL et al. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970;19(Suppl):789-830.
  2. Simpson SH et al. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population based cohort study. CMAJ 2006;174:169-74

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.